Olmesartan Medoxomil / Amlodipine / Hctz Win Medica (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil / Amlodipine / Hctz Win Medica, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑agent therapy is insufficient. GNH USA supplies Olmesartan Medoxomil / Amlodipine / Hctz Win Medica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil / Amlodipine / Hctz Win Medica is provided by GNH USA, a certified exporter adhering to Good Distribution Practice standards for global markets.

Olmesartan Medoxomil / Amlodipine / Hctz Win Medica is used in the management of hypertension, a condition characterized by elevated arterial pressure. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive heart disease: helps prevent left‑ventricular hypertrophy and related complications. - Hypertensive chronic kidney disease: assists in slowing renal function decline associated with high blood pressure.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Peripheral edema, often noticeable in the ankles or lower legs. - Headache, typically mild and transient. - Flushing or a sensation of warmth. - Fatigue or general tiredness. - Increased urination due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension leading to fainting or shock. - Acute kidney injury manifested by sudden rise in serum creatinine. - Electrolyte disturbances such as hyponatremia or hyperkalemia. - Angio‑edema affecting the face, lips, tongue or airway. - Liver enzyme elevations indicating possible hepatotoxicity. - Blood disorders such as agranulocytosis or thrombocytopenia.

Before starting therapy, patients should be assessed for renal function, electrolyte balance, and cardiovascular status. - Monitor blood pressure: ensure adequate control without excessive lowering. - Review kidney function: adjust dosing if creatinine clearance is reduced. - Check electrolytes: watch for sodium, potassium, and magnesium abnormalities. - Evaluate for heart failure: avoid rapid volume depletion in decompensated patients. - Counsel on orthostatic dizziness: advise rising slowly from sitting or lying positions. - Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and light.

Olmesartan Medoxomil / Amlodipine / Hctz Win Medica may interact with several medicines that influence blood pressure or electrolyte balance.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: additive risk of hyperkalaemia and renal impairment. - Potassium‑rich supplements or salt substitutes: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Lithium: thiazide component may raise lithium concentrations. - Antidiabetic drugs: diuretic‑induced volume changes may alter glucose control. - Alcohol: may enhance hypotensive effect. - Digoxin: thiazide‑induced electrolyte shifts can predispose to digoxin toxicity.